Salidroside
Phase 2Small molecule
Salidroside is one of 33 small molecule programs targeting Pregnancy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Pregnancy
#DrugCompanyPhaseTrials
1Femara
NovartisApproved
Bayer Aspirin
BayerApproved
Marinol
Jazz PharmaceuticalsApproved
Rayos
RRoxane Laboratories
Approved
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
BEYFORTUS
SanofiPhase 3
Monoferric
PPharmacosmos A/S
Phase 3
Dihydroartemisinin-Piperaquine
GSKPhase 3
Cimzia
UCBPhase 2
Sulfadoxine Pyrimethamine
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Salidroside. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details